# Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate

> **NCT00139061** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 128 (—)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Torcetrapib/Atorvastatin
- **DRUG:** Fenofibrate

## Key facts

- **NCT ID:** NCT00139061
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 128 (—)
- **Last updated:** 2007-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00139061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00139061, "Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT00139061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*